Table 2.
Characteristics of cats with azotemic CKD grouped according to magnesium status
| Variable (reference interval) | Hypomagnesemic (n = 20) | Normomagnesemic (n = 143) | Hypermagnesemic (n = 11) | |||
|---|---|---|---|---|---|---|
| Total magnesium (1.73–2.57 mg/dL) | 1.57 [1.41, 1.66] | 20 | 2.07 [1.92, 2.24] | 143 | 2.87 [2.70, 3.60] | 11 |
| Age (years) | 16.6 [15.0, 18.2]a | 19 | 14.8 [12.0, 16.2] | 130 | 12.0 [9.8, 15.0]b | 11 |
| Weight (kg) | 2.98 [2.51, 3.56]a | 19 | 3.92 [3.14, 4.61]b | 142 | 3.63 [3.25, 4.20] | 9 |
| BCS (1–9) | 3 [3, 4] | 10 | 4 [3, 5] | 90 | 3 [3, 5] | 5 |
| Sex (male, n [%]) | 7 (35) | 20 | 72 (50) | 143 | 7 (64) | 11 |
| Albumin (2.5–4.5 g/dL) | 3.0 [2.8, 3.3] | 20 | 3.1 [2.9, 3.3] | 143 | 3.0 [2.9, 3.3] | 11 |
| Chloride (100–124 mEq/L) | 117 [116, 119] | 20 | 118 [116, 120] | 143 | 117 [114, 122] | 11 |
| Cholesterol (85–154 mg/dL) | 234 [190, 277] | 20 | 199 [158, 246] | 143 | 212 [170, 247] | 11 |
| Creatinine (0.23–2.00 mg/dL) | 2.85 [2.32, 4.03]a | 20 | 2.48 [2.25, 2.96]a | 143 | 4.82 [2.65, 5.47]b | 11 |
| FGF23 (56–700 pg/mL) | 4950 [1931, 15893]a | 20 | 637 [351, 1941]b | 143 | 2658 [684, 8582] | 11 |
| FGF23 excess (n [%]) | 18 (90)a | 20 | 68 (48)b | 143 | 8 (73) | 11 |
| Globulin (2.5–4.5 g/dL) | 4.4 [4.1, 4.9]a | 20 | 4.7 [4.3, 5.3] | 143 | 4.8 [4.5, 6.2]b | 11 |
| PCV (30%–45%) | 30 [24, 34] | 20 | 34 [30, 37] | 141 | 32 [23, 34] | 11 |
| Phosphate (2.79–6.81 mg/dL) | 5.51 [4.47, 6.93]a | 20 | 4.43 [3.75, 5.39]b | 143 | 6.16 [4.46, 9.54]a | 11 |
| Hyperphosphatemia (% [n]) | 14 (70) | 20 | 64 (45) | 143 | 7 (64) | 11 |
| Potassium (3.5–5.5 mEq/L) | 3.9 [3.7, 4.4] | 20 | 4.1 [3.7, 4.3] | 143 | 4.0 [3.4, 4.8] | 11 |
| Hypokalemia (n [%]) | 2 (10) | 20 | 17 (12) | 143 | 3 (27) | 11 |
| Hyperkalemia (n [%]) | 0 (0) | 20 | 0 (0) | 143 | 1 (9) | 11 |
| PTH (2.6–17.6 pg/mL) | 46.3 [12.5, 93.0]a | 17 | 15.2 [6.5, 31.2]b | 138 | 25.0 [11.7, 81.9] | 10 |
| SRHPT (n [%]) | 12 (71) | 17 | 67 (49) | 138 | 6 (60) | 10 |
| SBP (<160 mm Hg) | 153 [134, 163] | 20 | 142 [128, 156] | 143 | 136 [128, 150] | 11 |
| Hypertension (n [%]) | 9 (45)a | 20 | 26 (18)b | 143 | 2 (18) | 11 |
| Sodium (145–157 mEq/L) | 154 [153, 155] | 20 | 153 [152, 155] | 143 | 151 [150, 156] | 11 |
| Total calcium (8.2–11.8 mg/dL) | 10.7 [10.1, 11.0]a | 20 | 10.2 [9.7, 10.5] | 143 | 9.6 [9.4, 10.4]b | 11 |
| Hypocalcemia (n, [%]) | 0 (0) | 20 | 1 (1) | 143 | 0 (0) | 11 |
| Hypercalcemia (n, [%]) | 1 (5) | 20 | 2 (1) | 143 | 0 (0) | 11 |
| Total protein (6.0–8.0 g/dL) | 7.6 [7.1, 7.9]a | 20 | 7.8 [7.5, 8.3]b | 143 | 8.2 [7.6, 9.1]b | 11 |
| UPC (<0.20) | 0.31 [0.27, 0.61]a | 13 | 0.17 [0.12, 0.32]b | 115 | 0.50 [0.23, 1.19]a | 9 |
| UPC <0.20 (n [%]) | 1 (8)a | 13 | 70 (61)b | 115 | 1 (11)a | 9 |
| UPC >0.40 (n [%]) | 5 (39) | 13 | 21 (18)a | 115 | 5 (56)b | 9 |
| USG (≥1.035) | 1.016 [1.014, 1.020] | 19 | 1.018 [1.016, 1.021] | 136 | 1.016 [1.014, 1.018] | 10 |
| UTI (n, [%]) | 1 (5) | 19 | 15 (11) | 136 | 0 (0) | 10 |
| Progressive CKD (n [%]) | 7 (88)a | 8 | 19 (28)b | 67 | 3 (75) | 4 |
| Survival time (days) | 147 [52, 328]a | 19 | 559 [205, 879]b | 120 | 125 [50, 423]a | 11 |
| Follow‐up (days) | 152 [53, 336]a | 20 | 546 [207, 890]b | 143 | 125 [50, 423]a | 11 |
| Year of diagnosis | 2008 [2004, 2011] | 20 | 2009 [2007, 2011] | 143 | 2008 [2003, 2012] | 11 |
Data presented as median [25th, 75th percentile] or prevalence (n [%]). Rows bearing a different superscript letter are significantly different from one another.
Abbreviations: BCS, body condition score; FGF23, fibroblast growth factor 23; PCV, packed cell volume; PTH, parathyroid hormone; SRHPT, secondary renal hyperparathyroidism; SBP, systolic blood pressure; UPC, urine protein to creatinine ratio; USG, urine specific gravity; UTI, bacterial urinary tract infection.